Kinetic

BPC-157 vs KPV half-life

BPC-157 has an elimination half-life of about 30 min; KPV has about 1 h. KPV is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory effects; BPC-157 is a 15-amino-acid synthetic peptide. Both have short estimated half-lives.

Side by side

BPC-157KPV
Half-life30 min (range 8–30 min)1 h
RouteSC / oralSC / oral
CategoryHealing & repairHealing & repair
EvidenceLimitedAnecdotal
Remaining after 24 hours<0.01%<0.01%
Remaining after 7 days<0.01%<0.01%
~97% cleared (5 half-lives)2.5 h5 h
Steady state (4-5 half-lives)2 h to 2.5 h4 h to 5 h

Single-dose decay

Share of one dose remaining over time, assuming first-order elimination. Dashed lines mark each half-life.

BPC-157 vs KPV single-dose decay 0% 25% 50% 75% 100% 0 1 h 2 h 3 h 4 h 5 h

BPC-157 (t½ 30 min) KPV (t½ 1 h)

BPC-157: Rat/dog PK only: plasma half-life under 30 minutes. Many protocols assume ~4 h; adjust if preferred. KPV: No human PK; estimate.

Model BPC-157 doses Model KPV doses

FAQ

Which lasts longer, BPC-157 or KPV?

KPV lasts longer. Its half-life is about 1 h, versus 30 min for BPC-157, roughly 2 times longer.

How long do BPC-157 and KPV stay in your system?

With first-order elimination, about 97% of a single dose is cleared after five half-lives: roughly 2.5 h for BPC-157 and 5 h for KPV. Individual clearance varies.

How long until BPC-157 and KPV reach steady state?

With consistent repeated dosing, levels approach steady state after 4 to 5 half-lives: about 2 h to 2.5 h for BPC-157, and 4 h to 5 h for KPV.

How reliable are these half-lives?

BPC-157: Limited evidence. KPV: Anecdotal evidence. Anecdotal values are community estimates and may be far off.

Related comparisons